Oncology News | pharmaphorum

News

Clovis hit by bladder cancer fail for Rubraca

Clovis Oncology’s hopes of a carving out a niche for its PARP inhibitor Rubraca in bladder cancer, away from its rivals in the class, have hit a setback.

News

J&J gets US okay for first targeted bladder cancer drug

Johnson & Johnson’s Balversa has become the first targeted therapy for bladder cancer after an FDA approval at the tail end of last week for patients with mutations in the FGFR gene.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

EU regulators to fast-track Janssen's multiple myeloma CAR-T

European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage trial results.

News

Fusion raises $105m for radiopharmaceutical trials

Radiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to deliver a lethal dose of radiation to cancer cells is also gaining increas

News

Clovis' Rubraca is latest PARP drug showing promise in pancr...

Clovis Oncology’s Rubraca has become the latest PARP drug to show potential in pancreatic cancer, as pharma companies seek new uses outside ovarian cancer where this class first gained a fo

News

NICE recommends interim funding for Lilly's breast cancer dr...

Final draft guidance from NICE has recommended interim NHS funding for Eli Lilly’s Verzenios (abemaciclib) with fulvestrant, giving certain breast cancer patients an option that can delay c

Clovis hit by bladder cancer fail for Rubraca

J&J gets US okay for first targeted bladder cancer drug

EU regulators to fast-track Janssen's multiple myeloma CAR-T

Fusion raises $105m for radiopharmaceutical trials

Clovis' Rubraca is latest PARP drug showing promise in pancr...

NICE recommends interim funding for Lilly's breast cancer dr...

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks